# VivoSense

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vivosense

- Industry: Software
- Headquarters: Newport Beach, US
- Website: www.vivosense.com
- Total disclosed funding: $25M
- Latest round: Series A (Mar 30, 2022)
- Investors on record: 2

## About

Founded in 2010 and based in California, US, VivoSense, Inc. offers a technology platform that helps researchers to collect and analyze wearable sensor data for regulated clinical trials and healthcare research. In March 2022, VivoSense, Inc. raised USD 25 million in Series A funding co-led by Debiopharm Innovation Fund and Perceptive Advisors. As of March 2022, the company is led by its CEO Dudley Tabakin.

The company's product is the VivoSense® software which is a regulatory compliant platform for researchers that need to analyze wearable sensor data and derive clinical biomarkers and real-world evidence (RWE). The company also provides services including clinical study design, sensor data collection, data quality control, and agile data analysis.

The company plans to use the Series A funding to accelerate the development of digital clinical measures from wearable and remote monitoring technologies.

## Funding rounds

- Series A, Mar 30, 2022, $25M — Perceptive Advisors, Debiopharm Innovation Fund

## Investors

- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A
- Debiopharm Innovation Fund (https://capitalatlas.ai/funds/debiopharm-innovation-fund) — Series A